Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas

NCT04656730 is registered in ClinicalTrials.gov with Hospital Vall d'Hebron as lead sponsor.

NCT NCT04656730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04656730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
Lead sponsor
Hospital Vall d'Hebron
Phase
Phase 4
Overall status
Completed
Start date
September 3, 2020
Completion date
January 31, 2023
Enrollment
68 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

functional dyspepsia, irritable bowel syndrome